BioHarvest Sciences Inc (CSE:BHSC) (OTCMKTS:CNVCF) (FRA:8MV) has said that VINIA, its red grape cell functional food, is the “only dietary supplement in the US market” which reduces the endothelin 1 (ET1) enzyme, and increases the nitric oxide (NO) molecules, in order to “increase the dilation of arteries and thereby improve blood flow.”
The Vancouver-based company explained that the presence of ET1 constricts a blood vessel, whereas the presence of nitric oxide dilates it. As a result of its "double-action effect," demonstrated by the Flow Mediated Dilatation measurements in a double-blinded placebo-controlled clinical trial and in an in-vitro study, whose results were both published, VINIA is “uniquely positioned to combat the aging process caused by a reduction in blood flow,” noted the company.
As people age, their bodies produce more ET1 (a vaso-constrictor) and less nitric oxide (a vaso-dilator), causing arteries and blood vessels to constrict and stiffen. This stiffening can reduce blood flow, which impacts the functioning of many of the body's organs as it reduces the supply of oxygen and nutrients carried by the blood to the entire body and its tissues.
According to BioHarvest, VINIA can therefore act as an “important anti-aging supplement,” in addition to providing other metabolic benefits. “Improvement of blood and oxygen supply benefits all of the body's organs and tissues and contributes to overall health and wellness,” said the company.
"At BioHarvest, we develop products that are highly differentiated and clinically proven to benefit health and wellness," Dr Yochi Hagay, who is the CTO at BioHarvest, said in a statement.
"As a biotech innovator, we carefully research what molecules or compounds are available in plants or fruits with the potential to have functional and structural impact on the human body. We then not only apply our BioFarming technology to produce such compounds consistently, but we conduct clinical trials to prove their efficacy before we commercialize them. We then ensure to make functional claims that are scientifically and clinically based.”
VINIA is a proprietary red grape cell product containing the entire matrix of polyphenols contained in red grapes.
"We launched VINIA in the US in May 2021, but we have been monitoring all supplement products in the area of blood flow for many years," said BioHarvest CEO Ilan Sobel. "From everything we have observed in the market, we are confident that VINIA is the only dietary supplement in the US that has the 'double-action' effect on both the ET1 and the NO.”
VINIA is the first product in the world to contain Piceid Resveratrol from red grapes at levels in each capsule which is equivalent to the amount of Piceid Resveratrol in a bottle of red wine, bringing consumers the benefits of red wine with “the advantage of zero calories, zero sugar, and zero percent alcohol.”
“The composition of VINIA, with its Piceid Resveratrol from red grapes in addition to an entire matrix of powerful polyphenols, delivers superior results that translate into highly satisfied customers and a correspondingly high rate of customer retention,” said Sobel.
“Our superior product gives us significant differentiation and, as such, we expect to see the same level of enthusiasm for VINIA in the US market as we have experienced in Israel since our launch of VINIA in that market in October 2020."
Contact the author Uttara Choudhury at uttara@proactiveinvestors.com
Follow her on Twitter: @UttaraProactive